Page 1 SCAI Dr. Marc Zimmermann Department of Bioinformatics Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) Grid-enabled drug discovery.

Slides:



Advertisements
Similar presentations
SOMA2 – Drug Design Environment. Drug design environment – SOMA2 The SOMA2 project Tekes (National Technology Agency of Finland) DRUG2000 program.
Advertisements

1 Real World Chemistry Virtual discovery for the real world Joe Mernagh 19 May 2005.
© Fraunhofer Institute SCAI and other members of the SIMDAT consortium Data Grids for Process and Product Development using Numerical Simulation and Knowledge.
DRIVER Long Term Preservation for Enhanced Publications in the DRIVER Infrastructure 1 WePreserve Workshop, October 2008 Dale Peters, Scientific Technical.
Fighting Malaria With The Grid. Computing on The Grid The Internet allows users to share information across vast geographical distances. Using similar.
Analysis of High-Throughput Screening Data C371 Fall 2004.
Jürgen Sühnel Institute of Molecular Biotechnology, Jena Centre for Bioinformatics Jena / Germany Supplementary Material:
Future CAMD Workloads and their Implications for Computer System Design IEEE 6th Annual Workshop on Workload Characterization.
EGEE-II INFSO-RI Enabling Grids for E-sciencE EGEE and gLite are registered trademarks World-wide in silico drug discovery against.
INFSO-RI Enabling Grids for E-sciencE WISDOM mini-workshop Vincent Breton (CNRS-IN2P3, LPC Clermont-Ferrand) ISGC 2007 March 28th,
Structural Genomics – an example of transdisciplinary research at Stanford Goal of structural and functional genomics is to determine and analyze all possible.
SimDL: A Model Ontology Driven Digital Library for Simulation Systems Jonathan Leidig - Edward A. Fox Kevin Hall Madhav Marathe Henning Mortveit.
Jeffery Loo NLM Associate Fellow ’03 – ’05 chemicalinformaticsforlibraries.
1 BrainWave Biosolutions Limited Accelerating Life Science Research through Technology.
OMICS Group Contact us at: OMICS Group International through its Open Access Initiative is committed to make genuine and.
20/03/2008 Dept. of Pharmaceutics 1 APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY AND PROCESS RESEARCH Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Associate.
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
The South African Malaria Initiative A Case Study E Jane Morris Bridging the Gap in Global Health Innovation - from Needs to.
Overview of Bioinformatics A/P Shoba Ranganathan Justin Choo National University of Singapore A Tutorial on Bioinformatics.
GGAGATTCTGGGCCACTTTGGTTCCCCATGAGCCAAGACGGCACTTCTAATTTGCATTCCCTACCGGAGTCCCTGTCTGTAGCCAGCCTGGCTTTCAGCTGGTGCCCAAAGTGACAAATGTATCTGCAATGACAAAGGTAC CCTGGAAGGGCTCGCCCTCTGCGGAATTTCAGTTCATGCAGGCCTTGGTGCTTCCACATCTGTCCAAGGGCCTTTCAAATGTGACTTTTAACTCTGTGGATTGATTTGCCCGG
Formal Empirical Applied Mathematical and technical methods and theories Cognitive, behavioral, and organizational techniques and theories ImagingBioInformaticsClinical.
Asia’s Largest Global Software & Services Company Genomes to Drugs: A Bioinformatics Perspective Sharmila Mande Bioinformatics Division Advanced Technology.
Development of Bioinformatics and its application on Biotechnology
1 Common Challenges Across Scientific Disciplines Laurence Field CERN 18 th November 2013.
FKPPL workshop May 2012 BUI The Quang Prof. Vincent Breton Prof. Doman Kim Prof. NGUYEN Hong Quang Prof. PHAM Quoc Long Grid enabled in silico drug discovery.
IST E-infrastructure shared between Europe and Latin America Biomedical Applications in EELA Esther Montes Prado CIEMAT (Spain)
CS 790 – Bioinformatics Introduction and overview.
EGEE-II INFSO-RI Enabling Grids for E-sciencE EGEE and gLite are registered trademarks Building Grid-enabled Virtual Screening Service.
INFSO-RI Enabling Grids for E-sciencE WHO, 2/11/04 Grid enabled in silico drug discovery Vincent Breton CNRS/IN2P3 Credit for the.
Protein Molecule Simulation on the Grid G-USE in ProSim Project Tamas Kiss Joint EGGE and EDGeS Summer School.
INFSO-RI Enabling Grids for E-sciencE V. Breton, 30/08/05, seminar at SERONO Grid added value to fight malaria Vincent Breton EGEE.
Function first: a powerful approach to post-genomic drug discovery Stephen F. Betz, Susan M. Baxter and Jacquelyn S. Fetrow GeneFormatics Presented by.
20/03/2008 Dept. of Pharmaceutics 1. Use of BIOINFORMATICS in Pharmaciutics 2  Presented By  Shafnan Nazar  Hamid Nasir 
Open source software and web services for designing therapeutic molecules G. P. S. Raghava, Head Bioinformatics Centre, Institute of Microbial Technology,
SEEK Welcome Malcolm Atkinson Director 12 th May 2004.
INFSO-RI Enabling Grids for E-sciencE In silico docking on EGEE infrastructure, the case of WISDOM Nicolas Jacq LPC of Clermont-Ferrand,
EGEE-II INFSO-RI Enabling Grids for E-sciencE WISDOM in EGEE-2, biomed meeting, 2006/04/28 WISDOM : Grid-enabled Virtual High Throughput.
INFSO-RI Enabling Grids for E-sciencE Grid-enabled drug discovery to address neglected diseases N. Jacq – CNRS-IN2P3 EGAAP meeting.
ACGT: Open Grid Services for Improving Medical Knowledge Discovery Stelios G. Sfakianakis, FORTH.
INFSO-RI Enabling Grids for E-sciencE EGEE Review WISDOM demonstration Vincent Bloch, Vincent Breton, Matteo Diarena, Jean Salzemann.
B i o i n f o r m a t i c s / B i o m e d i c a l A p p l i c a t i o n s i n E E L A Mexico, D.F., october 22 – 26, e – s c i e n c e M e x i c.
BIOINFOGRID: Bioinformatics Grid Application for life science MILANESI, Luciano National Research Council Institute of.
An Overview of Scientific Workflows: Domains & Applications Laboratoire Lorrain de Recherche en Informatique et ses Applications Presented by Khaled Gaaloul.
Collaborative Tools for the Grid V.N Alexandrov S. Mehmood Hasan.
High throughput biology data management and data intensive computing drivers George Michaels.
Milanesi Luciano Catania, Italy 13/03/2007 Bioinformatics challenges in European projects in Grid. Milanesi Luciano National Research Council Institute.
The presentation is prepared by: Andrey Voronkov, PhD – speaker (MIPT, Lomonosov Moscow State University) Vladimir Barinov – Grid Dynamics.
Docking and Virtual Screening Using the BMI cluster
신기술 접목에 의한 신약개발의 발전전망과 전략 LGCI 생명과학 기술원. Confidential LGCI Life Science R&D 새 시대 – Post Genomic Era Genome count ‘The genomes of various species including.
Genomic Medicine Grid Juan Pedro Sánchez Merino Instituto de Salud Carlos III
N. Jacq Laboratoire de Physique Corpusculaire – CNRS HealthGrid session of LSG-RG - GGF12 - Brussels September 22nd 2004 Grid-enabled drug discovery to.
Molecular Modeling in Drug Discovery: an Overview
The opportunities and challenges of sharing genomics data with the pharmaceutical industry Shahid Hanif, Head of Health Data & Outcomes, ABPI DNA digest.
FESR Consorzio COMETA - Progetto PI2S2 Molecular Modelling Applications Laura Giurato Gruppo di Modellistica Molecolare (Prof.
Designing Drugs Virtually P14D461P - Arni B. Hj. Morshidi P14D389P - Anisah Bt Ismail P14D397P - Syarifah Rohaya Bt Wan Idris P14D394P - Dayang Adelina.
Page 1 Computer-aided Drug Design —Profacgen. Page 2 The most fundamental goal in the drug design process is to determine whether a given compound will.
Dr. George Geromichalos, Ph.D.
The Dengue Docking Project: Virtual Screening on the ProtoGRID
Similarities between Grid-enabled Medical and Engineering Applications
ATOM Accelerating Therapeutics for Opportunities in Medicine
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
Discovery and Development of Medicines
Ontology-Based Information Integration Using INDUS System
Virtual Screening.
“Structure Based Drug Design for Antidiabetics”
1st International Conference on Semantics, Knowledge and Grid
Grid Application Model and Design and Implementation of Grid Services
In silico docking on grid infrastructures
Consortium: National networks in 16 European countries.
Next Generation Sequencing Market. Report Description and Highlights According to Renub Research market research report “Next Generation Sequencing (NGS)
Presentation transcript:

page 1 SCAI Dr. Marc Zimmermann Department of Bioinformatics Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) Grid-enabled drug discovery to address neglected diseases

page 2 SCAI The challenges of the drug discovery A pharmaceutical grid for the drug discovery A pharmaceutical grid for a neglected disease Content

page 3 SCAI Target Identification Target Validation Lead Identification Lead Optimization Target discoveryLead discovery vHTS Similarity analysis Similarity analysis Database filtering Database filtering Computer Aided Drug Design (CADD) de novo design diversity selection diversity selection Biophores Alignment Combinatorial libraries ADMET QSAR Phases of a pharmaceutical development Clinical Phases (I-III) Duration: 12 – 15 years, Costs: million US $

page 4 SCAI Enable scientists to quickly and easily find compounds binding to a particular target protein -growth of targets number -growth of 3D structures determination (PDB database) -growth of computing power -growth of prediction quality of protein-compound interactions Experimental screening very expensive : not for academic or small companies Aim : Enrichment = Actives molecules Tested molecules Computational aspects of Drug Discovery : virtual screening

page 5 SCAI Dataflow and workflow in a virtual screening hit crystal structure ligand data base junk docking Structure optimization Reranking MD-simulation

page 6 SCAI The challenges of the drug discovery A pharmaceutical grid for the drug discovery A pharmaceutical grid for a neglected disease Content

page 7 SCAI To guarantee and preserve knowledge in the areas of discovery, development, manufacturing, marketing and sales of next drug therapies -Provides extremely large CPU power to perform computing intense tasks in a transparent way by means of an automated job submission and distribution facility -Provides transparent and secure access to storage and archiving of large amounts of data in an automated and self-organized mode -Connects, analyses and structure data and metadata in a transparent mode according to pre-defined rules (science or business process based) A shared in silico resource

page 8 SCAI Semantic inconsistence between biological and chemical databases => ontology-based mediation services Meta-information on softwares and formats Users integration from different and heterogeneous organisations Statistical models, optimization Grid engine Virtual screening machine with formal description Construction in function of the disease/subject of the grid Structure of a grid for drug discovery

page 9 SCAI Content The challenges of the drug discovery A pharmaceutical grid for the drug discovery A pharmaceutical grid for a neglected disease

page 10 SCAI Overview on neglected diseases Infectious diseases kill 14 million people each year, more than 90% of whom are in the developing world. Access to treatment is problematic -the medicines are unaffordable, -some have become ineffective due to drug resistance, -and others are not appropriately adapted to specific local conditions and constraints. Neglected diseases represent grave personal tragedies and substantial health and economic burdens even for the wealthiest nations. Drug discovery and development targeted at infectious and parasitic diseases in poor countries has virtually ground to a standstill, so that these diseases are neglected.

page 11 SCAI In silico drug discovery process (EGEE, SwissBioGRID, …) Clermont-Ferrand The grid impact : Computing and storage resources for genomics research and in silico drug discovery cross-organizational collaboration space to progress research work Federation of patient databases for clinical trials and epidemiology in developing countries Grids for rare diseases and diseases of the developing world Support to local centres in plagued areas (genomics research, clinical trials and vector control) SCAI Fraunhofer Swiss Biogrid consortium Local research centres In plagued areas

page 12 SCAI Collaborative environment We will support such processes as: -search of new drug targets through post-genomics requiring data management and computing -providing a large public database with drug like molecules and found hits -massive docking to search for new drugs requiring high performance computing and data storage -handling of experimental data requiring data storage and management

page 13 SCAI Acknowledgement IN2P3/CNRS Nicolas Jacq Jean Salzeman Vincent Breton Fraunhofer SCAI Marc Zimmermann Kai Kumpf Martin Hofmann Biozentrum Basel Michael Podvinec Torsten Schwede